Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Do Hedge Funds and Insiders Love Markel Corporation (NYSE:MKL)?

Is Markel Corporation (NYSE:MKL) ready to raly soon? Investors who are in the know are in a bullish mood. The number of long hedge fund bets advanced by 1 recently.

In the 21st century investor’s toolkit, there are many methods shareholders can use to watch stocks. A pair of the best are hedge fund and insider trading movement. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite investment managers can outclass the market by a very impressive amount (see just how much).

Markel Corporation (NYSE:MKL)

Equally as important, optimistic insider trading activity is a second way to break down the investments you’re interested in. There are many motivations for an upper level exec to sell shares of his or her company, but just one, very simple reason why they would buy. Several empirical studies have demonstrated the impressive potential of this strategy if you know what to do (learn more here).

With these “truths” under our belt, we’re going to take a gander at the key action encompassing Markel Corporation (NYSE:MKL).

What have hedge funds been doing with Markel Corporation (NYSE:MKL)?

At year’s end, a total of 18 of the hedge funds we track held long positions in this stock, a change of 6% from one quarter earlier. With the smart money’s positions undergoing their usual ebb and flow, there exists a few noteworthy hedge fund managers who were boosting their stakes meaningfully.

When looking at the hedgies we track, Robert Joseph Caruso’s Select Equity Group had the largest position in Markel Corporation (NYSE:MKL), worth close to $132 million, accounting for 2.1% of its total 13F portfolio. On Select Equity Group’s heels is Charles Akre of Akre Capital Management, with a $101 million position; 2% of its 13F portfolio is allocated to the company. Other hedgies with similar optimism include Chuck Royce’s Royce & Associates, Brian Ashford-Russell and Tim Woolley’s Polar Capital and Ken Griffin’s Citadel Investment Group.

As industrywide interest jumped, specific money managers were breaking ground themselves. Halcyon Asset Management, managed by John Bader, assembled the most valuable position in Markel Corporation (NYSE:MKL). Halcyon Asset Management had 9 million invested in the company at the end of the quarter. Sander Gerber’s Hudson Bay Capital Management also initiated a $1 million position during the quarter. The only other fund with a brand new MKL position is Paul Tudor Jones’s Tudor Investment Corp.

How are insiders trading Markel Corporation (NYSE:MKL)?

Bullish insider trading is at its handiest when the primary stock in question has experienced transactions within the past six months. Over the latest half-year time frame, Markel Corporation (NYSE:MKL) has experienced 3 unique insiders purchasing, and 1 insider sales (see the details of insider trades here).

With the returns exhibited by the aforementioned strategies, everyday investors must always pay attention to hedge fund and insider trading sentiment, and Markel Corporation (NYSE:MKL) is an important part of this process.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 29.2% between September 2012 and February 2013 versus 8.7% for the S&P 500 index. Try it now by clicking the link above.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!